TY - JOUR
T1 - Mortality of Invasive Pneumococcal Disease following Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Greenland
AU - Alexandrova Nikolova, Kristiana
AU - Andersson, Mikael
AU - Slotved, Hans Christian
AU - Koch, Anders
N1 - Funding Information:
Hans-Christian Slotved is involved with projects supported by Pfizer. All other authors declare no conflict of interest.
Funding Information:
This research was funded by Independent Research Fund Denmark grant number 0168-0019B, the Grosserer L.F. Foghts Fond grant number 21.778, the Dagmar Marshall Fond grant number J.nr.-500020 and J.nr.-131120, the Fonden af 1870 grant number RL-WSDOCS.FID1290380, the Ville Heise Legat grant number M18-19, the Aase og Ejnar Danielsens Fond grant number 20100179, and the Holms Mindelegat grant number 20064.
Publisher Copyright:
© 2024 by the authors.
PY - 2024/2
Y1 - 2024/2
N2 - Before the incorporation of the 13-valent pneumococcal conjugate vaccine (PCV13) into the childhood vaccination regimen in Greenland in 2010, Inuit populations experienced a substantial prevalence of invasive pneumococcal disease (IPD). The PCV13 introduction has been shown to markedly reduce the incidence of IPD. This current study estimated the impact of PCV13 introduction on IPD mortality in Greenland. This was a nationwide register-based study using all available data on IPD cases 1995–2020 in Greenland. Thirty-one-day IPD case fatality rates (CFR), and all-cause and mortality rates associated with IPD during the period before the introduction of PCV13 (January 1995 to September 2010) were compared with those observed in the post-PCV13 era (September 2010 to October 2020). Standardized mortality ratios (SMRs) expressed differences in mortality by sex, age, region, ethnicity, comorbidity, and serotype. IPD CFR decreased with 24.5% from the pre- to the post-PCV13 period. SMR in IPD patients decreased by 57% (95% CI, 36–75%), and a reduction occurred in all age groups. While SMR in IPD persons ≥60 years remained virtually unchanged, there were no IPD-related deaths in persons ≤39 years in the post-PCV13 period. In conclusion, IPD-related mortality has decreased in Greenland following PCV13 introduction in 2010 in the country.
AB - Before the incorporation of the 13-valent pneumococcal conjugate vaccine (PCV13) into the childhood vaccination regimen in Greenland in 2010, Inuit populations experienced a substantial prevalence of invasive pneumococcal disease (IPD). The PCV13 introduction has been shown to markedly reduce the incidence of IPD. This current study estimated the impact of PCV13 introduction on IPD mortality in Greenland. This was a nationwide register-based study using all available data on IPD cases 1995–2020 in Greenland. Thirty-one-day IPD case fatality rates (CFR), and all-cause and mortality rates associated with IPD during the period before the introduction of PCV13 (January 1995 to September 2010) were compared with those observed in the post-PCV13 era (September 2010 to October 2020). Standardized mortality ratios (SMRs) expressed differences in mortality by sex, age, region, ethnicity, comorbidity, and serotype. IPD CFR decreased with 24.5% from the pre- to the post-PCV13 period. SMR in IPD patients decreased by 57% (95% CI, 36–75%), and a reduction occurred in all age groups. While SMR in IPD persons ≥60 years remained virtually unchanged, there were no IPD-related deaths in persons ≤39 years in the post-PCV13 period. In conclusion, IPD-related mortality has decreased in Greenland following PCV13 introduction in 2010 in the country.
KW - case fatality rate
KW - Inuit
KW - invasive pneumococcal disease
KW - IPD
KW - mortality
KW - mortality rate
KW - PCV13
KW - pneumococcal conjugate vaccine
KW - pneumococcal serotypes
KW - standardized mortality ratio
UR - http://www.scopus.com/inward/record.url?scp=85185668139&partnerID=8YFLogxK
U2 - 10.3390/vaccines12020179
DO - 10.3390/vaccines12020179
M3 - Journal article
AN - SCOPUS:85185668139
SN - 2076-393X
VL - 12
JO - Vaccines
JF - Vaccines
IS - 2
M1 - 179
ER -